1.Slots J. Periodontitis: facts, fallacies and the future. Periodontol 2000. 2017;75:7–23.
2.Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89(Suppl 1):S173–S182.
3.Page RC, Offenbacher S, Schroeder HE, et al. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000. 1997;14:216–248.
4.Kwon T, Lamster IB, Levin L. Current Concepts in the Management of Periodontitis. Int Dent J. 2021;71(6):462-476.
5.Sanz M, Marco Del Castillo A, Jepsen S, Gonzalez-Juanatey JR, D'Aiuto F, Bouchard P, Chapple I, Dietrich T, Gotsman I, Graziani F, Herrera D, Loos B, Madianos P, Michel JB, Perel P, Pieske B, Shapira L, Shechter M, Tonetti M, Vlachopoulos C, Wimmer G. Periodontitis and cardiovascular diseases: Consensus report. J Clin Periodontol. 2020;47(3):268-288.
6.戴振宁,郑蔚晗,利时雨.核因子κB受体活化因子配体和肿瘤坏死因子α经炎性牙周膜干细胞外泌体促进破骨细胞分化[J].华西口腔医学杂志,2022,40(04):377-385.
7.邹浩冬,杨飞,张莞嫣,等.高迁移率族蛋白B1在牙周炎中作用机制的研究进展[J].成都医学院学报,2023,18(03):404-408.
8.湛济帆,田艾.巨噬细胞集落刺激因子-1及其受体在牙周炎中的研究进展[J].口腔医学研究,2024,40(03):199-205.
9.赵聪,杨森,罗佳,等.唑来膦酸对牙周炎大鼠破骨细胞活化的影响及相关机制[J].临床和实验医学杂志,2021,20(15):1585-1588.
10.覃浩,亢腾,刘钢.长链非编码RNA通过p38MAPK信号通路直接或间接影响骨质疏松症[J].中国组织工程研究,2025,29(01):175-184.
11.王梦蝶,吴虹,王荣慧,等.RANKL介导的诱导破骨细胞分化的相关经典信号通路研究进展[J].中国药理学通报,2020,36(07):898-902.
12.任莉荣,徐永清.破骨细胞分化机制的研究进展[J].中国骨质疏松杂志,2015,21(12):1522-1525+1528.
13.屈泽超,王栋,冯铭哲,等.破骨细胞分化信号传导及相关天然化合物的研究进展[J].中国骨质疏松杂志,2023,29(02):282-287+296.
14.杨羽晨,杨佩佩,黄碧莹,等.丝裂原活化蛋白激酶信号通路介导的自噬可调节破骨细胞的增殖分化和功能[J].中国组织工程研究,2021,25(26):4192-4197.
15.杨城,李玮民,冉栋成,等.LncRNA与信号通路在骨质疏松症发生机制中的研究进展[J].中华骨质疏松和骨矿盐疾病杂志,2024,17(01):67-74.
16.陈锋,任国武,章晓云,等.核因子κB受体活化因子信号转导机制与破骨细胞的活化[J].中国组织工程研究,2023,27(02):293-299.
17.屈泽超,王栋,冯铭哲,等.破骨细胞分化信号传导及相关天然化合物的研究进展[J].中国骨质疏松杂志,2023,29(02):282-287+296.
18.Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidinevs midazolam for sedation of critically ill patients: a ran-domized trial[J]. JAMA, 2009, 301(5): 489-499.
19.Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007,40:251–64.
20.Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003,423:337–42.
21.Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell,2002,3:889–901.
22.Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet,2003,4:638–49.
23.Khan, O., et al., TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature, 2019,571(7764): 211-218.
24.Liang, C., et al., Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia. Front Oncol, 2021,11: 740642.
25.Meng, Y., et al., CD155 blockade improves survival in experimental sepsis by reversing dendritic cell dysfunction. Biochem Biophys Res Commun, 2017,490(2): 283-289.
26.Liao, J., et al., Polymorphisms in the TOX3/LOC643714 and risk of breast cancer in south China. Int J Biol Markers, 2018,1724600818755633.
27.Khan, O., et al., TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature, 2019. 571(7764): p. 211-218.
28.Yu, H., et al., Hepatocellular Carcinoma Cell-Derived Exosomal miR-21-5p Induces Macrophage M2 Polarization by Targeting RhoB. Int J Mol Sci, 2023. 24(5):4593.